ADCY4 Atherosclerosis Mouse Study

A 2026 basic-research paper identified adenylate cyclase 4, or ADCY4, as a flow-responsive gene that may restrain inflammation in the cells lining arteries. The researchers combined RNA-sequencing analysis, cultured human endothelial-cell experiments and mouse atherosclerosis models. They also reported that semaglutide increased ADCY4 expression under disturbed-flow conditions and reduced inflammation and plaque formation in their experimental systems. Those effects were substantially weakened when endothelial ADCY4 was absent^[1]. This is mechanistic evidence from cells and mice. It is not a clinical trial, and it does not show that targeting ADCY4 prevents heart attacks or treats plaque in people.

What question the researchers asked

Atherosclerotic plaques do not form evenly along every artery. The paper starts from the observation that endothelial dysfunction is especially important in regions exposed to disturbed blood flow. The endothelium is the thin cell layer lining blood vessels. The researchers asked whether ADCY4 responds to the mechanical pattern of flow and then changes inflammatory signaling during plaque development^[1].

ADCY4 is an enzyme that produces cyclic adenosine monophosphate, usually shortened to cAMP. This small signaling molecule can activate protein kinase A, or PKA, and influence many cell processes. The study focused on a proposed ADCY4 to cAMP to PKA pathway that restrains NF-kappaB, a signaling system involved in inflammatory gene activity^[1]. A pathway observed in a model can explain where to look next. It does not by itself prove a therapeutic effect in humans.

How the study tested ADCY4

The first layer was computational. The team integrated RNA-sequencing data from human vascular endothelial cells exposed either to unidirectional flow or disturbed flow. It also analyzed single-cell RNA-sequencing data from mouse carotid arteries after partial ligation, a procedure used to create altered flow. The researchers then measured ADCY4 expression in cultured endothelial cells under several flow conditions^[1]. These linked data sets were used to identify ADCY4 as a candidate flow-responsive gene.

ADCY4 expression rose under unidirectional flow and fell under disturbed flow. The investigators reported that KLF2, a flow-sensitive transcription factor, bound directly to the ADCY4 promoter and increased its transcription in human aortic endothelial cells. Knocking down ADCY4 under unidirectional flow increased inflammatory gene expression and monocyte adhesion. Overexpressing ADCY4 under disturbed flow produced changes in the opposite direction^[1]. Monocyte adhesion is a laboratory marker relevant to early vascular inflammation, not a clinical event.

The animal experiments used ApoE-deficient mice fed a high-fat diet, a common model that is prone to atherosclerosis. Nanoparticles delivered CRISPR-Cas9 components intended to remove Adcy4 specifically in endothelial cells. In the partial carotid-ligation model, loss of endothelial Adcy4 increased endothelial inflammation, monocyte infiltration and plaque formation. A separate high-fat-diet experiment also found larger lesions in whole-mounted aortas and aortic arches after endothelial Adcy4 knockout^[1]. The abstract supports the direction of these findings but does not provide group sizes, treatment timing or effect estimates.

Where semaglutide enters the paper

The semaglutide experiments were one part of the mechanistic program. Under disturbed flow, semaglutide increased ADCY4 expression in cultured human aortic endothelial cells. In the reported experimental models it also reduced vascular endothelial inflammation, monocyte accumulation and plaque formation^[1]. The paper therefore supports a specific hypothesis: endothelial ADCY4 may contribute to some anti-inflammatory and anti-atherosclerotic effects observed with semaglutide in these models.

The key intervention test was loss of the proposed mediator. When endothelial ADCY4 was absent, the reported beneficial effects of semaglutide were substantially impaired^[1]. That result strengthens the pathway argument inside the model because changing ADCY4 changed the response. It still does not establish that ADCY4 is the only mediator, that the same dependency exists in human arteries, or that manipulating this pathway would be safe.

Important details remain unavailable. The PubMed record does not report the semaglutide dose, exposure period, mouse group sizes or numerical plaque differences. The publisher page was not substantively accessible during our review, and the record has no PubMed Central full text, so we do not infer those details from the abstract. They are necessary for judging scale, precision and reproducibility and should be checked in the full paper before the result guides further experiments.

Why this is not a SELECT explanation

Human cardiovascular evidence for semaglutide comes from a different kind of research. In SELECT, 17,604 adults with established cardiovascular disease and overweight or obesity, but no diabetes, were randomized to semaglutide 2.4 mg or placebo. Over a mean follow-up of 39.8 months, the composite of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% of the semaglutide group and 8.0% of the placebo group^[2].

SELECT showed a clinical outcome difference in its enrolled population, but it did not test endothelial ADCY4 as the explanation. The new ADCY4 paper tested a possible biological route in experimental systems, but it did not measure cardiovascular events in people. Putting the two papers beside each other is useful only if that boundary remains clear. The mouse study cannot be used to claim that ADCY4 caused SELECT's result^[1][2].

The clinical trial also reported more permanent treatment discontinuations due to adverse events with semaglutide than placebo, 16.6% versus 8.2%^[2]. Mechanistic interest does not replace the need to weigh established indications, contraindications and adverse effects. Readers considering semaglutide under current regulation should discuss the approved clinical route with a qualified professional.

What we don't yet know

The next questions are substantial. Researchers need to establish whether ADCY4 behaves the same way across human artery regions and disease stages, whether its expression predicts outcomes, and whether the pathway can be altered without unwanted effects elsewhere. Independent replication should test the knockout strategy, plaque measurements and semaglutide response with complete quantitative reporting. Human tissue studies could then assess whether the model reflects clinical biology.

The honest readout is narrower than the opportunity label suggested. This paper has genuine semaglutide relevance, but only within a basic-research experiment. It proposes ADCY4 as one link between blood-flow patterns, endothelial inflammation and atherosclerosis. It does not create a new use for semaglutide, identify a patient group or provide treatment instructions. Its value is a testable mechanism.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.